Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1949 1
1950 2
1951 2
1952 1
1953 2
1954 4
1955 2
1958 1
1959 3
1960 2
1961 2
1962 3
1963 5
1964 2
1966 1
1967 1
1968 1
1969 2
1970 1
1976 1
1978 1
1979 1
1983 1
1995 1
1997 1
2009 2
2010 1
2011 1
2012 3
2013 2
2014 1
2015 4
2016 3
2017 2
2018 1
2019 4
2020 5
2021 4
2022 3
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
Diaz-Manera J, Kishnani PS, Kushlaf H, Ladha S, Mozaffar T, Straub V, Toscano A, van der Ploeg AT, Berger KI, Clemens PR, Chien YH, Day JW, Illarioshkin S, Roberts M, Attarian S, Borges JL, Bouhour F, Choi YC, Erdem-Ozdamar S, Goker-Alpan O, Kostera-Pruszczyk A, Haack KA, Hug C, Huynh-Ba O, Johnson J, Thibault N, Zhou T, Dimachkie MM, Schoser B; COMET Investigator Group. Diaz-Manera J, et al. Lancet Neurol. 2021 Dec;20(12):1012-1026. doi: 10.1016/S1474-4422(21)00241-6. Lancet Neurol. 2021. PMID: 34800399 Clinical Trial.
Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial.
Kishnani PS, Diaz-Manera J, Toscano A, Clemens PR, Ladha S, Berger KI, Kushlaf H, Straub V, Carvalho G, Mozaffar T, Roberts M, Attarian S, Chien YH, Choi YC, Day JW, Erdem-Ozdamar S, Illarioshkin S, Goker-Alpan O, Kostera-Pruszczyk A, van der Ploeg AT, An Haack K, Huynh-Ba O, Tammireddy S, Thibault N, Zhou T, Dimachkie MM, Schoser B; COMET Investigator Group. Kishnani PS, et al. JAMA Neurol. 2023 Jun 1;80(6):558-567. doi: 10.1001/jamaneurol.2023.0552. JAMA Neurol. 2023. PMID: 37036722 Free PMC article. Clinical Trial.
Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection.
Reiter RJ, Sharma R, Simko F, Dominguez-Rodriguez A, Tesarik J, Neel RL, Slominski AT, Kleszczynski K, Martin-Gimenez VM, Manucha W, Cardinali DP. Reiter RJ, et al. Among authors: neel rl. Cell Mol Life Sci. 2022 Feb 20;79(3):143. doi: 10.1007/s00018-021-04102-3. Cell Mol Life Sci. 2022. PMID: 35187603 Free PMC article. Review.
Individual differences in fundamental social motives.
Neel R, Kenrick DT, White AE, Neuberg SL. Neel R, et al. J Pers Soc Psychol. 2016 Jun;110(6):887-907. doi: 10.1037/pspp0000068. Epub 2015 Sep 14. J Pers Soc Psychol. 2016. PMID: 26371400
Family Matters: Rethinking the Psychology of Human Social Motivation.
Ko A, Pick CM, Kwon JY, Barlev M, Krems JA, Varnum MEW, Neel R, Peysha M, Boonyasiriwat W, Brandstätter E, Crispim AC, Cruz JE, David D, David OA, de Felipe RP, Fetvadjiev VH, Fischer R, Galdi S, Galindo O, Golovina G, Gomez-Jacinto L, Graf S, Grossmann I, Gul P, Hamamura T, Han S, Hitokoto H, Hřebíčková M, Johnson JL, Karl JA, Malanchuk O, Murata A, Na J, O J, Rizwan M, Roth E, Salgado SAS, Samoylenko E, Savchenko T, Sevincer AT, Stanciu A, Suh EM, Talhelm T, Uskul AK, Uz I, Zambrano D, Kenrick DT. Ko A, et al. Among authors: neel r. Perspect Psychol Sci. 2020 Jan;15(1):173-201. doi: 10.1177/1745691619872986. Epub 2019 Dec 3. Perspect Psychol Sci. 2020. PMID: 31791196
79 results